|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate that a certain level of expression of TNF-R75 is necessary for obtaining TNF-alpha-mediated tumor cell lysis in the absence of TNF-R75.
|
9685865 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TrkA and p75 were positively correlated and were respectively associated with the histoprognostic grading and the tumor type.
|
11389056 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TrkA and p75 showed no association with tumor grade, Fédération Internationale des Gynaecologistes et Obstetristes stage, chemotherapy status, the extent of residual disease, or survival (P > 0.05).
|
11705863 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, p75 expression was less frequent in effusions compared to both primary tumors and lymph node metastases, significantly so for the latter (p = 0.019).
|
14997042 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, our results document for the first time frequent expression of p-TrkA and lower expression of p75 in MM, in agreement with the biological aggressiveness of this tumor.
|
15084380 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p75 neurotrophin receptor (p75NTR) is a proximate cell membrane receptor glycoprotein that has been identified as a tumor and metastasis suppressor.
|
15342406 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, p75(NTR) protein was not detected in any tumor studied, unlike normal retina.
|
16555252 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed the following: i) TrkA and TrkB expression was significantly higher in AR-negative compared to AR-positive cells; ii) TrkA and TrkB expression was related to the invasive capacity/malignancy of PCa cells; iii) p75 NGFR could be considered a tumor suppressor gene which is present at high levels only in AR-positive cells; and iv) that NGF and BDNF (targeting TrkA/p75 NTR and TrKB, respectively) induced cell migration and this was inhibited by the CEP-701 treatment.
|
17143529 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, p75 expression was substantially reduced in a subset of tumors and cell lines, in particular compared to its expression in normal retina.
|
17973327 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The number of TNFalpha mRNA, TNFR2 mRNA and TNFR2/R7 mRNA copies were estimated in tumour and healthy tissue.
|
18088549 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p75 neurotrophin receptor (p75(NTR)) functions as a tumor suppressor in prostate epithelial cells, where its expression declines with progression to malignant cancer.
|
18974393 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In an unrelated cohort of 110 neuroblastic tumors, p75 mRNA expression levels correlated with differentiation, and patients with tumors that expressed p75 at high levels had an increased event-free and overall survival.
|
19142969 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types.
|
19738070 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, metastasis to the lung was observed in a few cases following development of mammary tumors in p75 CUX1 transgenic mice.
|
20224295 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Clinical response was predicted by tumor size (p = 0,002), lymph node metastasis (p = 0.007), distant metastasis (p = 0.001) and disease stage (p < 0.001), but TNFRSF1B A1466G genotype was independent of these factors.
|
20646319 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further stepwise multivariate Cox regression analysis showed that the TNFRSF1B +676 GG was an independent prognosis predictor in this NSCLC cohort (GG vs. GT/TT: HR = 0.35, 95% CI = 0.14-0.85), in the presence of node status (N2-3 vs. N0-1: HR = 1.60, 95% CI = 1.09-2.35) and tumor stage (T3-4 vs. T0-2: HR = 1.48, 95% CI = 1.08-2.03).
|
21995493 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The increased expression of p75 neurotrophin receptor (NTR) is a characteristic of high-grade glioma, but the potential significance of increased p75NTR in this tumor is not fully understood.
|
23576602 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TNFR1 and TNFR2 were mainly localized in the epithelial neoplastic cells of the tumor.
|
24511008 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The interaction of tumor necrosis factor-α (TNF-α) with its receptors: TNFRSF1A and TNFRSF1B is critical for the promotion of tumor growth, invasion and metastasis.
|
25010932 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BF-rTK + GCV induced tumor apoptosis mediated by FasL and TNFR2 through the mitochondrial control of apoptosis via Bid and Bim without inducing necroptosis and autophagy.
|
27464624 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In such animals, TNFR2-specific agonists inhibited tumor growth, enhanced tumor infiltration by CD8+ T cells and increased CD8+ T cell IFN-γ synthesis.
|
27626702 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro and in vivo fluorescence imaging results suggest peptide P75 modified magnetosomes (Mag-P75) specifically bind to MDA-MB-468 and SKBR3 cells as well as xenograft tumors with surprisingly low accumulation in other organs including liver and kidney.
|
27888699 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These TNFR2 antibodies killed T<sub>regs</sub> isolated from ovarian cancer ascites more potently than it killed T<sub>regs</sub> from healthy donor samples, suggesting that these antibodies may have specificity for the tumor microenvironment.
|
28096513 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Clinical Relevance of a Candidate Stem Cell Marker, p75 Neurotrophin Receptor (p75NTR) Expression in Circulating Tumor Cells.
|
28560678 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TNFR2 expression (P=0.017), age (P=0.011), menopausal status (P<0.0001), tumor size (P=0.016), clinical stage (P=0.005), pathological grade (P=0.002) and estrogen/progesterone receptor and HER2 triple-status (P=0.008) were all shown to significantly impact the DFS rate of patients with BC.
|
28789455 |
2017 |